Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis.

ABSTRACT:

Background

Macrophages play a pivotal role in atherosclerotic plaque development. Recent evidence has suggested the glucagon-like peptide-1 receptor (GLP-1R) agonist, liraglutide, can attenuate pro-inflammatory responses in macrophages. We hypothesized that liraglutide could limit atherosclerosis progression in vivo via modulation of the inflammatory response.

Methods

Human THP-1 macrophages and bone marrow-derived macrophages, from both wild-type C57BL/6 (WT) and apolipoprotein E null mice (ApoE^-/-) were used to investigate the effect of liraglutide on the inflammatory response in vitro. In parallel, ApoE^-/- mice were fed a high-fat (60% calories from fat) high-cholesterol (1%) diet for 8 weeks to induce atherosclerotic disease progression with/without

SUBMITTER: Bruen R 

PROVIDER: S-EPMC5674826 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature